Advertisement

Biochemistry (Moscow)

, Volume 83, Issue 2, pp 152–158 | Cite as

2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors

  • D. K. Nilov
  • K. I. Yashina
  • I. V. Gushchina
  • A. L. Zakharenko
  • M. V. Sukhanova
  • O. I. Lavrik
  • V. K. ŠvedasEmail author
Article

Abstract

We show for the first time that natural 2,5-diketopiperazines (cyclic dipeptides) can suppress the activity of the important anticancer target poly(ADP-ribose)polymerase (PARP). Cyclo(L-Ala-L-Ala) and cyclo(L-Ala-D-Ala) can interact with the key residues of the PARP-1 active site, as demonstrated using docking and molecular dynamics simulations. One of the amide groups of cyclo(L-Ala-L-Ala) and cyclo(L-Ala-D-Ala) forms hydrogen bonds with the Gly863 residue, while the second amide group can form a hydrogen bond with the catalytic residue Glu988, and the side chain can make a hydrophobic contact with Ala898. Newly identified diketopiperazine inhibitors are promising basic structures for the design of more effective inhibitors of PARP family enzymes. The piperazine core with two chiral centers provides many opportunities for structural optimization.

Keywords

diketopiperazine piperazinedione poly(ADP-ribose)polymerase inhibitor molecular modeling docking molecular dynamics 

Abbreviation (biaoti)

PARP

poly(ADP-ribose)polymerase.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

10541_2018_578_MOESM1_ESM.pdf (176 kb)
2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors

References

  1. 1.
    Prasad, C. (1995) Bioactive cyclic dipeptides, Peptides, 16, 151–164.CrossRefPubMedGoogle Scholar
  2. 2.
    Minelli, A., Bellezza, I., Grottelli, S., and Galli, F. (2008) Focus on cyclo(His-Pro): history and perspectives as antioxidant peptide, Amino Acids, 35, 283–289.CrossRefPubMedGoogle Scholar
  3. 3.
    Borthwick, A. D., and Da Costa, N. C. (2017) 2,5-Diketopiperazines in food and beverages: taste and bioactivity, Crit. Rev. Food Sci. Nutr., 57, 718–742.CrossRefPubMedGoogle Scholar
  4. 4.
    Martins, M. B., and Carvalho, I. (2007) Diketopiperazines: biological activity and synthesis, Tetrahedron, 63, 9923–9932.CrossRefGoogle Scholar
  5. 5.
    Borthwick, A. D. (2012) 2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products, Chem. Rev., 112, 3641–3716.CrossRefPubMedGoogle Scholar
  6. 6.
    Dinsmore, C. J., and Beshore, D. C. (2002) Recent advances in the synthesis of diketopiperazines, Tetrahedron, 58, 3297–3312.CrossRefGoogle Scholar
  7. 7.
    Rodionov, I. L., Rodionova, L. N., Baidakova, L. K., Romashko, A. M., Balashova, T. A., and Ivanov, V. T. (2002) Cyclic dipeptides as building blocks for combinatorial libraries. Part 2: Synthesis of bifunctional diketopiperazines, Tetrahedron, 58, 8515–8523.CrossRefGoogle Scholar
  8. 8.
    Khimiuk, A. Y., Korennykh, A. V., Van Langen, L. M., Van Rantwijk, F., Sheldon, R. A., and Švedas, V. K. (2003) Penicillin acylase-catalyzed peptide synthesis in aqueous medium: a chemo-enzymatic route to stereoisomerically pure diketopiperazines, Tetrahedron Asymmetry, 14, 3123–3128.CrossRefGoogle Scholar
  9. 9.
    Coward, R. M., and Carson, C. C. (2008) Tadalafil in the treatment of erectile dysfunction, Ther. Clin. Risk Manag., 4, 1315–1330.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Borthwick, A. D. (2010) Oral oxytocin antagonists, J. Med. Chem., 53, 6525–6538.CrossRefPubMedGoogle Scholar
  11. 11.
    Watson, C., Jenkinson, S., Kazmierski, W., and Kenakin, T. (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor, Mol. Pharmacol., 67, 1268–1282.CrossRefPubMedGoogle Scholar
  12. 12.
    Nicholson, B., Lloyd, G. K., Miller, B. R., Palladino, M. A., Kiso, Y., Hayashi, Y., and Neuteboom, S. T. (2006) NPI-2358 is a tubulin-depolymerizing agent: in vitro evidence for activity as a tumor vascular-disrupting agent, Anticancer Drugs, 17, 25–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Hayashi, Y., Yamazaki-Nakamura, Y., and Yakushiji, F. (2013) Medicinal chemistry and chemical biology of diketopiperazine-type antimicrotubule and vascular-disrupting agents, Chem. Pharm. Bull. (Tokyo), 61, 889–901.CrossRefGoogle Scholar
  14. 14.
    Hassa, P. O., Haenni, S. S., Elser, M., and Hottiger, M. O. (2006) Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going, Microbiol. Mol. Biol. Rev., 70, 789–829.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hassler, M., and Ladurner, A. G. (2012) Towards a structural understanding of PARP1 activation and related signaling ADP-ribosyl-transferases, Curr. Opin. Struct. Biol., 22, 721–729.CrossRefPubMedGoogle Scholar
  16. 16.
    Drenichev, M. S., and Mikhailov, S. N. (2016) Poly(ADP-ribose): from chemical synthesis to drug design, Bioorg. Med. Chem. Lett., 26, 3395–3403.CrossRefPubMedGoogle Scholar
  17. 17.
    Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., Soto, M., and Perez, J. M. (2006) Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy, Recent Pat. Anticancer Drug Discov., 1, 39–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Curtin, N. J., and Szabo, C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond, Mol. Aspects Med., 34, 1217–1256.CrossRefPubMedGoogle Scholar
  19. 19.
    Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., and Ashworth, A. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917–921.CrossRefPubMedGoogle Scholar
  20. 20.
    Martin, S. A., Lord, C. J., and Ashworth, A. (2008) DNA repair deficiency as a therapeutic target in cancer, Curr. Opin. Genet. Dev., 18, 80–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Ame, J. C., Spenlehauer, C., and De Murcia, G. (2004) The PARP superfamily, Bioessays, 26, 882–893.CrossRefPubMedGoogle Scholar
  22. 22.
    Schreiber, V., Dantzer, F., Ame, J. C., and De Murcia, G. (2006) Poly(ADP-ribose): novel functions for an old molecule, Nat. Rev. Mol. Cell Biol., 7, 517–528.CrossRefPubMedGoogle Scholar
  23. 23.
    Jagtap, P., and Szabo, C. (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors, Nat. Rev. Drug Discov., 4, 421–440.CrossRefPubMedGoogle Scholar
  24. 24.
    Ferraris, D. V. (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic, J. Med. Chem., 53, 4561–4584.CrossRefPubMedGoogle Scholar
  25. 25.
    Malyuchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., and Studitskiy, V. M. (2015) PARP1 inhibitors: antitumor drug design, Acta Naturae, 7, 27–37.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Banasik, M., and Ueda, K. (1994) Inhibitors and activators of ADP-ribosylation reactions, Mol. Cell. Biochem., 138, 185–197.CrossRefPubMedGoogle Scholar
  27. 27.
    Frampton, J. E. (2015) Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer, BioDrugs, 29, 143–150.CrossRefPubMedGoogle Scholar
  28. 28.
    Sehouli, J., Braicu, E. I., and Chekerov, R. (2016) PARP inhibitors for recurrent ovarian carcinoma: current treatment options and future perspectives, Geburtshilfe Frauenheilkd., 76, 164–169.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wang, Y. Q., Wang, P. Y., Wang, Y. T., Yang, G. F., Zhang, A., and Miao, Z. H. (2016) An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy, J. Med. Chem., 59, 9575–9598.CrossRefPubMedGoogle Scholar
  30. 30.
    Nilov, D. K., Tararov, V. I., Kulikov, A. V., Zakharenko, A. L., Gushchina, I. V., Mikhailov, S. N., Lavrik, O. I., and Švedas, V. K. (2016) Inhibition of poly(ADP-ribose)polymerase by nucleic acid metabolite 7-methylguanine, Acta Naturae, 8, 108–115.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Sletten, E. (1970) Conformation of cyclic dipeptides. The crystal and molecular structures of cyclo-D-alanyl-L-alanyl and cyclo-L-alanyl-L-alanyl (3,6-dimethylpiperazine-2,5-dione), J. Am. Chem. Soc., 92, 172–177.CrossRefGoogle Scholar
  32. 32.
    Stroganov, O. V., Novikov, F. N., Stroylov, V. S., Kulkov, V., and Chilov, G. G. (2008) Lead finder: an approach to improve accuracy of protein–ligand docking, binding energy estimation, and virtual screening, J. Chem. Inf. Model., 48, 2371–2385.CrossRefPubMedGoogle Scholar
  33. 33.
    Novikov, F. N., Stroylov, V. S., Stroganov, O. V., Kulkov, V., and Chilov, G. G. (2009) Developing novel approaches to improve binding energy estimation and virtual screening: a PARP case study, J. Mol. Model., 15, 1337–1347.CrossRefPubMedGoogle Scholar
  34. 34.
    Case, D. A., Darden, T. A., Cheatham, T. E., Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Walker, R. C., Zhang, W., Merz, K. M., Roberts, B., Hayik, S., Roitberg, A., Seabra, G., Swails, J., Gotz, A. W., Kolossvary, I., Wong, K. F., Paesani, F., Vanicek, J., Wolf, R. M., Liu, J., Wu, X., Brozell, S. R., Steinbrecher, T., Gohlke, H., Cai, Q., Ye, X., Wang, J., Hsieh, M.-J., Cui, G., Roe, D. R., Mathews, D. H., Seetin, M. G., Salomon-Ferrer, R., Sagui, C., Babin, V., Luchko, T., Gusarov, S., Kovalenko, A., and Kollman, P. A. (2012) AMBER 12, University of California, San Francisco.Google Scholar
  35. 35.
    Case, D. A., Cheatham, T. E., 3rd, Darden, T., Gohlke, H., Luo, R., Merz, K. M., Jr., Onufriev, A., Simmerling, C., Wang, B., and Woods, R. J. (2005) The Amber biomolecular simulation programs, J. Comput. Chem., 26, 1668–1688.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Voevodin, V. V., Zhumatiy, S. A., Sobolev, S. I., Antonov, A. S., Bryzgalov, P. A., Nikitenko, D. A., Stefanov, K. S., and Voevodin, V. V. (2012) Practice of “Lomonosov” super-computer, Open Systems J. (Moscow), 7, 36–39.Google Scholar
  37. 37.
    Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple Amber force fields and development of improved, Proteins, 65, 712–725.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Crowley, M. F., Darden, T. A., Cheatham, T. E., and Deerfield, D. W. (1997) Adventures in improving the scaling and accuracy of a parallel molecular dynamics program, J. Supercomput., 11, 255–278.CrossRefGoogle Scholar
  39. 39.
    Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD–visual molecular dynamics, J. Mol. Graph., 14, 33–38.CrossRefPubMedGoogle Scholar
  40. 40.
    Kinoshita, T., Nakanishi, I., Warizaya, M., Iwashita, A., Kido, Y., Hattori, K., and Fujii, T. (2004) Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase, FEBS Lett., 556, 43–46.CrossRefPubMedGoogle Scholar
  41. 41.
    Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A. G., Pol, E., Frostell, A., Ekblad, T., Oncu, D., Kull, B., Robertson, G. M., Pellicciari, R., Schuler, H., and Weigelt, J. (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors, Nat. Biotechnol., 30, 283–288.CrossRefPubMedGoogle Scholar
  42. 42.
    Ekblad, T., Lindgren, A. E., Andersson, C. D., Caraballo, R., Thorsell, A. G., Karlberg, T., Spjut, S., Linusson, A., Schuler, H., and Elofsson, M. (2015) Towards small molecule inhibitors of mono-ADP-ribosyltransferases, Eur. J. Med. Chem., 95, 546–551.CrossRefPubMedGoogle Scholar
  43. 43.
    Stark, T., and Hofmann, T. (2005) Structures, sensory activity, and dose/response functions of 2,5-diketopiperazines in roasted cocoa nibs (Theobroma cacao), J. Agric. Food Chem., 53, 7222–7231.CrossRefPubMedGoogle Scholar
  44. 44.
    Stark, T., Bareuther, S., and Hofmann, T. (2006) Molecular definition of the taste of roasted cocoa nibs (Theobroma cacao) by means of quantitative studies and sensory experiments, J. Agric. Food Chem., 54, 5530–5539.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen, Y. H., Liou, S. E., and Chen, C. C. (2004) Two-step mass spectrometric approach for the identification of diketopiperazines in chicken essence, Eur. Food Res. Technol., 218, 589–597.CrossRefGoogle Scholar
  46. 46.
    Li, X. J., Tang, H. Y., Duan, J. L., Gao, J. M., and Xue, Q. H. (2013) Bioactive alkaloids produced by Pseudomonas brassicacearum subsp. neoaurantiaca, an endophytic bacterium from Salvia miltiorrhiza, Nat. Prod. Res., 27, 496–499.CrossRefPubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • D. K. Nilov
    • 1
  • K. I. Yashina
    • 2
  • I. V. Gushchina
    • 2
  • A. L. Zakharenko
    • 3
  • M. V. Sukhanova
    • 3
  • O. I. Lavrik
    • 3
  • V. K. Švedas
    • 1
    • 2
    Email author
  1. 1.Belozersky Institute of Physico-Chemical BiologyLomonosov Moscow State UniversityMoscowRussia
  2. 2.Faculty of Bioengineering and BioinformaticsLomonosov Moscow State UniversityMoscowRussia
  3. 3.Institute of Chemical Biology and Fundamental MedicineSiberian Branch of the Russian Academy of SciencesNovosibirskRussia

Personalised recommendations